-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Reiterates Neutral on NovoCure, Maintains $18 Price Target

Benzinga·01/15/2026 14:03:52
Listen to the news
Wedbush analyst David Nierengarten reiterates NovoCure (NASDAQ:NVCR) with a Neutral and maintains $18 price target.